JP2021534200A - 脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドghrp6とを含む薬学的組合せ - Google Patents
脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドghrp6とを含む薬学的組合せ Download PDFInfo
- Publication number
- JP2021534200A JP2021534200A JP2021509876A JP2021509876A JP2021534200A JP 2021534200 A JP2021534200 A JP 2021534200A JP 2021509876 A JP2021509876 A JP 2021509876A JP 2021509876 A JP2021509876 A JP 2021509876A JP 2021534200 A JP2021534200 A JP 2021534200A
- Authority
- JP
- Japan
- Prior art keywords
- ghrp6
- egf
- combination
- body weight
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 title claims abstract description 54
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title claims abstract description 54
- 101800003838 Epidermal growth factor Proteins 0.000 title claims abstract description 49
- 229940116977 epidermal growth factor Drugs 0.000 title claims abstract description 49
- 208000029028 brain injury Diseases 0.000 title claims abstract description 21
- 230000006931 brain damage Effects 0.000 title claims abstract description 16
- 231100000874 brain damage Toxicity 0.000 title claims abstract description 16
- 102000009024 Epidermal Growth Factor Human genes 0.000 title claims abstract 9
- 230000003248 secreting effect Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 claims abstract description 49
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000037396 body weight Effects 0.000 claims description 62
- 206010008118 cerebral infarction Diseases 0.000 claims description 27
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 26
- 238000003745 diagnosis Methods 0.000 claims description 15
- 230000000302 ischemic effect Effects 0.000 claims description 15
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 7
- 208000028389 Nerve injury Diseases 0.000 claims description 6
- 230000008764 nerve damage Effects 0.000 claims description 6
- 230000011514 reflex Effects 0.000 claims description 6
- 101710111255 Appetite-regulating hormone Proteins 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 230000009747 swallowing Effects 0.000 claims description 5
- 230000000472 traumatic effect Effects 0.000 claims description 5
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 4
- 208000028782 Hereditary disease Diseases 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 208000030137 articulation disease Diseases 0.000 claims description 2
- 230000003930 cognitive ability Effects 0.000 claims description 2
- 238000009593 lumbar puncture Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 18
- 210000002569 neuron Anatomy 0.000 abstract description 13
- 230000000144 pharmacologic effect Effects 0.000 abstract description 10
- 230000007246 mechanism Effects 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 6
- 210000003169 central nervous system Anatomy 0.000 abstract description 6
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 40
- WZHKXNSOCOQYQX-KAGZITNASA-N growth hormone releasing hexapeptide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-KAGZITNASA-N 0.000 description 39
- 210000004556 brain Anatomy 0.000 description 31
- 238000011084 recovery Methods 0.000 description 31
- 230000000926 neurological effect Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000000324 neuroprotective effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 102000000802 Galectin 3 Human genes 0.000 description 7
- 108010001517 Galectin 3 Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000037906 ischaemic injury Diseases 0.000 description 5
- 210000004498 neuroglial cell Anatomy 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 102000013271 Hemopexin Human genes 0.000 description 4
- 108010026027 Hemopexin Proteins 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000001767 medulla oblongata Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002537 thrombolytic effect Effects 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 238000012313 Kruskal-Wallis test Methods 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 206010060860 Neurological symptom Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010013887 Dysarthria Diseases 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010050081 Neonatal hypoxia Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000008132 psychomotor development Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000000580 secretagogue effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000016554 Cytoglobin Human genes 0.000 description 1
- 108010053020 Cytoglobin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000037087 Excitatory amino acid transporters Human genes 0.000 description 1
- 108091006291 Excitatory amino acid transporters Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102100031903 Neudesin Human genes 0.000 description 1
- 101710090805 Neudesin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000231663 Puffinus auricularis Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000037420 neurological improvement Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
周辺部虚血性領域内のEGF−GHRP6の組合せによる処置の効果を知るために、エンドセリン1の脳内注射によって誘発された限局性脳梗塞を有するラットを対象に実験を行った。エンドセリン1を脳内注射した2時間後、EGF−GHRP6の組合せ(0.6μg/kg体重のEGF及び40μg/kg体重のGHRP6、n=9)又はビヒクル(n=10)を用いて、ラットを処置した。両実験群を追跡し、言及された薬学的組合せによる処置の3、5及び24時間後に、偽手術群の動物と一緒に、各群の動物を殺処分した。全動物の脳組織ホモジネートを調製し、3つの群にプールした。以下の手順を行った:総タンパク質量、酵素消化、液体クロマトグラフィー/質量分析(LC−MS/MS)によるペプチド混合物の分析、及びタンパク質同定。後者は、MS/MSスペクトルに基づく配列データベースで実行し、Swissprotデータベースのドブネズミ(Rattus norvegicus)分類体系(29 982のタンパク質、2016年4月)に対する検索を減らした。無料の標識定量のために、Perseusプログラムv.1.5.2.6を統計的ツールとして使用した。各タンパク質について定量化された3つ以上の複製を考慮した。偽対照動物に関して、又はEGF−GHRP6の組合せを用いて処置された動物と処置されていない動物との間で、目的の各状態についてペアード検定を行った。変化因子が1.5以上でp値が0.05未満のタンパク質については、帰無仮説を棄却した。有意な変化を伴うタンパク質群については、5%のFDR(誤発見率)も考慮した。
EGF−GHRP6の組合せを用いて、虚血性病因の脳梗塞に罹患した患者50例を診断時から治療した。診断には、症状の発症後最大24時間の時間間隔を含めた。治療は1週間行い、12時間ごとに0.8μg/kg体重のEGFと50μg/kg体重のGHRP6との順次非経口的投与からなった。同じ投与スキームに従って、EGF−GHRP6の組合せ(10μg/kg体重のEGF及び5μg/kg体重のGHRP6)を用いて、患者35例の第2の群を治療した。基本的に症状及び合併症の治療である従来の治療法を用いて、虚血性病因の脳梗塞を有する患者42例の別の群を治療した。
筋萎縮性側索硬化症と確定診断された患者40例に、リルテック(登録商標)(リルゾール)とともに、1日おきに6カ月にわたり、0.6μg/kg体重のEGF及び60μg/kg体重のGHRP6を静脈内投与した。疾患の起源、脊髄(n=25)又は延髄(n=15)に従って、これらの患者を前もって層別化した。筋萎縮性側索硬化症と確定診断され、脊髄(n=21)又は延髄(n=9)の起源に従って層別化された患者30例の別の群も、リルテック(登録商標)のみを用いて治療した。
0.3μg/kg体重のEGF及び30μg/kg体重のGHRP6を用いて、出産前後期の様々な原因のために重度の脳低酸素症を発症した新生児の群を人道的に治療した(n=9)。治療は1週間行い、12時間ごとにEGF−GHRP6の組合せを非経口投与した。
Claims (17)
- 上皮成長因子(EGF)と成長ホルモン分泌促進物質ペプチドGHRP6とを含む、脳損傷を回復させるための薬学的組合せ。
- 体重1kg当たり0.3μg〜0.9μgのEGFと、体重1kg当たり30μg〜80μgのGHRP6とを含む、請求項1に記載の組合せ。
- EGF及びGHRP6が、非経口経路によって順次又は同時に投与される、請求項2に記載の組合せ。
- 非経口投与が、静脈内、髄腔内、脳室内、大槽内又は鼻腔内で行われる、請求項3に記載の組合せ。
- 髄腔内投与が、腰椎穿刺及び/又は前記経路による投与用に設計されたデバイスによって行われる、請求項4に記載の組合せ。
- a)EGF及び薬学的に許容される賦形剤を含む容器と、b)GHRP6及び薬学的に許容される賦形剤を含む容器とを含むキットからなる、請求項1に記載の組合せ。
- EGFを含む容器が5μg〜80μgのEGFを含み、GHRP6を含む容器が0.5mg〜6mgのGHRP6を含む、請求項6に記載の組合せ。
- 脳損傷を回復させるための薬学的組合せを製造するための、上皮成長因子(EGF)及び成長ホルモン分泌促進物質ペプチドGHRP6の使用。
- 組合せが、脳梗塞後の脳損傷を回復させるために用いられる、請求項8に記載の使用。
- 組合せの最初の投与が、脳梗塞の診断の最初の時点と診断から24時間後との間に行われる、請求項9に記載の使用。
- 組合せが、体重1kg当たり0.3μg〜0.9μgのEGFと、体重1kg当たり30μg〜80μgのGHRP6とを含む、請求項8に記載の使用。
- 上皮成長因子(EGF)と成長ホルモン分泌促進物質ペプチドGHRP6とを含む薬学的組合せの治療有効量が、それを必要とする患者に投与される、脳損傷を回復させる方法。
- 組合せが、体重1kg当たり0.3μg〜0.9μgのEGFと、体重1kg当たり30μg〜80μgのGHRP6とを含む、請求項12に記載の方法。
- 脳損傷が、虚血性、毒性、外科的性質、外傷性のものであるか、タンパク質症、遺伝性障害、又は永続的な神経損傷の他の原因によるものである、請求項12に記載の方法。
- 脳損傷が、脳梗塞、新生児における重度の脳低酸素症、又は筋萎縮性側索硬化症によって引き起こされる、請求項14に記載の方法。
- 組合せが、進行性の運動ニューロン疾患及び遅鈍性の運動ニューロン疾患の治療では、筋力、嚥下反射を改善し、構音障害を低減するために投与される、請求項12に記載の方法。
- 組合せが、ヒトの記憶、学習能力などの複雑な機能の保存、運動能力、感覚能力及び認知能力の回復のために投与される、請求項12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2018000092A CU24591B1 (es) | 2018-08-21 | 2018-08-21 | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
CU2018-0092 | 2018-08-21 | ||
PCT/CU2019/050006 WO2020038498A1 (es) | 2018-08-21 | 2019-08-16 | Combinación farmacéutica que contiene el factor de crecimiento epidérmico y el peptido secretagogo ghrp6 para la restauración del daño cerebral |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534200A true JP2021534200A (ja) | 2021-12-09 |
JP7299304B2 JP7299304B2 (ja) | 2023-06-27 |
Family
ID=68461694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021509876A Active JP7299304B2 (ja) | 2018-08-21 | 2019-08-16 | 脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドghrp6とを含む薬学的組合せ |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210196793A1 (ja) |
EP (1) | EP3842057A1 (ja) |
JP (1) | JP7299304B2 (ja) |
CN (1) | CN112912092B (ja) |
BR (1) | BR112021003028A2 (ja) |
CA (1) | CA3110169A1 (ja) |
CU (1) | CU24591B1 (ja) |
MX (1) | MX2021002063A (ja) |
WO (1) | WO2020038498A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531607A (ja) * | 2005-03-02 | 2008-08-14 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | 自己免疫障害後の中枢神経系の神経再生に用いるegf/ghrp−6の組合せ |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23157A1 (es) | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
-
2018
- 2018-08-21 CU CU2018000092A patent/CU24591B1/es unknown
-
2019
- 2019-08-16 CA CA3110169A patent/CA3110169A1/en active Pending
- 2019-08-16 WO PCT/CU2019/050006 patent/WO2020038498A1/es unknown
- 2019-08-16 JP JP2021509876A patent/JP7299304B2/ja active Active
- 2019-08-16 BR BR112021003028-0A patent/BR112021003028A2/pt unknown
- 2019-08-16 EP EP19797979.2A patent/EP3842057A1/en active Pending
- 2019-08-16 CN CN201980069096.8A patent/CN112912092B/zh active Active
- 2019-08-16 MX MX2021002063A patent/MX2021002063A/es unknown
- 2019-08-16 US US17/269,788 patent/US20210196793A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531607A (ja) * | 2005-03-02 | 2008-08-14 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | 自己免疫障害後の中枢神経系の神経再生に用いるegf/ghrp−6の組合せ |
Non-Patent Citations (2)
Title |
---|
RESTORATIVE NEUROLOGY AND NEUROSCIENCE, vol. 29, JPN6023023963, 2011, pages 243 - 252, ISSN: 0005080582 * |
RESTORATIVE NEUROLOGY AND NEUROSCIENCE, vol. 31, JPN6023008060, 2013, pages 213 - 223, ISSN: 0005002760 * |
Also Published As
Publication number | Publication date |
---|---|
CN112912092B (zh) | 2024-05-24 |
BR112021003028A2 (pt) | 2021-05-11 |
WO2020038498A1 (es) | 2020-02-27 |
CA3110169A1 (en) | 2020-02-27 |
EP3842057A1 (en) | 2021-06-30 |
CU20180092A7 (es) | 2020-04-02 |
CN112912092A (zh) | 2021-06-04 |
JP7299304B2 (ja) | 2023-06-27 |
CU24591B1 (es) | 2022-04-07 |
MX2021002063A (es) | 2021-04-28 |
US20210196793A1 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107847615B (zh) | 用于治疗cln2疾病的tpp1调配物及方法 | |
US7855176B1 (en) | Reduced volume formulation of glatiramer acetate and methods of administration | |
EP3137087B1 (en) | Estrogen combination for treatment of multiple sclerosis | |
US20210315932A1 (en) | Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products | |
JP2015522630A (ja) | 多発性硬化症治療のためのビオチンの使用 | |
JP2016188214A (ja) | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー | |
CN112566641A (zh) | 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物 | |
EP4374921A2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
JP7299304B2 (ja) | 脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドghrp6とを含む薬学的組合せ | |
JP2015514771A (ja) | 神経保護性組成物および使用方法 | |
RU2776812C1 (ru) | Фармацевтическая комбинация, включающая эпидермальный фактор роста и пептид ghrp6 в качестве стимулятора секреции, для восстановления после повреждения головного мозга | |
JP2020530846A (ja) | 方法 | |
Rettele et al. | Blindness, deafness, quadriparesis, and a retinal malformation: the ravages of neurofibromatosis 2 | |
EP1032402B1 (en) | Use of citicoline for the treatment of multiple sclerosis (MS) | |
van der Plas et al. | Baclofen-induced chorea in complex regional pain syndrome-related dystonia | |
RU2586286C2 (ru) | Применение для лечения и профилактики атеросклероза белково-пептидного комплекса (далее-бпк), полученного из эмбриональной нервной ткани или из быстрозамороженного эмбрионального мозга сельскохозяйственных копытных животных, влияющего на обратный транспорт холестерина из сосудистой стенки и профиль активации моноцитов у пациентов с выраженным атеросклерозом магистральных сосудов или с предрасположенностью к сердечно-сосудистым заболеваниям и способ профилактики и лечения пациентов с атеросклерозом артериальных сосудов и с заболеваниями, вызванными атеросклерозом магистральных и периферических сосудов головного мозга, сердца, сосудов нижних конечностей и аорты (два варианта) | |
Stanković et al. | Some of the risk factors for retinopathy of prematurity | |
US20220098291A1 (en) | Treatment of Parkinson's Disease | |
WO2021240204A1 (en) | Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy | |
Yadavmali et al. | The Lance-Adams syndrome: helpful or just hopeful, after cardiopulmonary arrest | |
Djurabaevna et al. | Influence of cortexin on the level of neurotrophic protein S100 in chronic cerebral ischemia | |
WO2006041838A2 (en) | Heparinoid compositions for treatment and prevention of dementia | |
Dzhaparalieva et al. | A CASE REPORT OF RARE FAMILIAL DEMYELINATING DISEASE | |
RU2208443C2 (ru) | Способ лечения рассеянного склероза | |
RU2361604C1 (ru) | Способ лечения атопического дерматита |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220518 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230322 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230609 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230615 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7299304 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |